Clinical trial NCT01766583: A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
Official title: A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Relapsed/Refractory B-cell Lymphoma
Keywords: Open label, 3 + 3 dose escalation study followed by an expansion phase.
Lead sponsor: The Lymphoma Academic Research Organisation
Sponsor class: OTHER
Collaborators: name: Celgene Corporation
First posted: 2013-01-11
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open label, 3 + 3 dose escalation study, to determine the MTD, safety, efficacy and PK profiles for subjects with relapsed/refractory B-cell malignancies when using CC-292 and lenalidomide combination therapy. Subjects will be followed for disease progression and collection of second primary malignancy (SPM) events. This dose escalation will be followed by an exploratory expansion phase in 3 cohorts of 12 patients each.


Eligibility criteria: Inclusion Criteria:

* Histology:

  1. Patients with any type of B-cell Lymphoma except CLL, SLL and Waldenström disease will be eligible during the dose escalation phase
  2. During the expansion phases, patients with DLBCL for cohort A, mantle cell lymphoma for cohort B and any other type of B-cell lymphoma except CLL, SLL and Waldenström disease for cohort C.
* Other criteria:

  * Signed inform consent
  * Patients should be relapsed or refractory NHL after ≥1 prior Rituximab-containing regimen for which no other type of therapy is of higher priority
  * Aged 18 years or more.
  * ECOG performance status 0-2.
  * Measurable disease defined by at least one single node or tumor lesion \> 1.5 cm.
  * Life expectancy of ≥ 90 days (3 months).
  * Patients must be eligible and willing to undergo excisional biopsies of tumor sites with a lymph node of minimum 1 cm at baseline and after 21 days of treatment
  * Females of childbearing potential (FCBP)† must have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL before starting lenalidomide - the first test must be performed within 10-14 days before starting lenalidomide treatment and the second test must be performed within 24 hours before starting lenalidomide
  * FCBP must either commit to continued abstinence from heterosexual intercourse or begin two methods of birth control, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to monthly pregnancy testing and must be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.
  * Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential. Men must also be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.

Exclusion Criteria:

Previous treatment with lenalidomide or a BTK inhibitor. Central nervous system or meningeal involvement. Contraindication to any drug contained in this regimen Concomitant use of medicines known to cause QT prolongation or torsades de pointes HIV disease, active hepatitis B or C. Any serious active disease or co-morbid medical condition (according to investigator's decision);

Any of the following laboratory abnormalities :

* Absolute neutrophil count (ANC) \< 1,500 cells/mm3 (1.5 x 109/L).
* Platelet count \< 80,000/mm3 (80 x 109/L)
* Serum SGOT/AST or SGPT/ALT \>3.0 x upper limit of normal (ULN).
* Serum total bilirubin \> 1.5 ULN except in case of hemolytic anemia and Gilbert's syndrome.

Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) of \< 50 mL /min Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast or Incidental histological finding of prostate cancer \[TNM stage of T1a or T1b\]) unless the subject has been free of the disease for ≥ 5 years Any serious medical condition, laboratory abnormality, or psychiatric illnessthat would prevent the subject from signing the informed consent form.

Pregnant or lactating females. Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide and/or pomalidomide.

Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide and/or pomalidomide.

Subjects with ≥ Grade 2 neuropathy. Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation (Day 1) of study drug therapy.

Chronic use of proton pump inhibitors, H2 antagonists or antacids or their use in the last 7 days prior to the first CC-292 dose. Patients with chronic gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease, should be carefully evaluated for their suitability for this treatment prior to enrollment in this study. These medications should be avoided throughout the study.

Patients taking corticosteroids during the 4 weeks prior to inclusion, unless administered at a dose equivalent of ≤ 10 mg/day prednisone (over these 4 weeks).

Primary outcomes:
measure: Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma
timeFrame: 28 days
Secondary outcomes:
measure: preliminary efficacy signals of the CC-292 + Lenalidomide combination
timeFrame: 6 months
measure: Observed maximum plasma concentration
timeFrame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose
measure: time to reach maximum observed plasma concentration (Tmax)
timeFrame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose
measure: Terminal phase rate constant (λz)
timeFrame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose
measure: plasma decay half-life (t1/2)
timeFrame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose
measure: Area under the curve from time zero to the last quantifiable concentration [AUC(0-t)]
timeFrame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose
measure: Area under the curve from time zero to extrapolated infinity [AUC(0-∞)]
timeFrame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose
measure: BTk receptor occupancy
timeFrame: 0 (predose) and 21 days post dose
Other outcomes:
Locations:
city: Créteil
country: France
facility: Hopital henri mondor
city: Lille
country: France
facility: CHU de Lille
city: Marseille
country: France
facility: Institut Paoli Calmette
city: Nantes
country: France
facility: CHU de Nantes
city: Pierre Bénite
country: France
facility: CHU Lyon Sud
city: Toulouse
country: France
facility: CHU de Toulouse
Study officials:
affiliation: CHU Lyon - Sud - LYSA
name: Gilles Salles, PhD
role: STUDY_CHAIR
affiliation: CHU de Toulouse LYSA
name: Loïc YSEBAERT, MD
role: STUDY_CHAIR
References: